Daniel Allen Magee

US Patent:

20210295979, Sep 23, 2021

Filed:

May 28, 2021

Appl. No.:

17/334483

Inventors:

- Irving TX, US
David Spetzler - Paradise Valley AZ, US
Anthony Helmstetter - Gilbert AZ, US
Wolfgang Michael Korn - Mill Valley CA, US
Daniel Magee - Phoenix AZ, US

Assignee:

CARIS MPI, INC. - Irving TX

International Classification:

G16H 20/40
G16B 20/10
G16B 40/00
G06N 20/00

Abstract:

Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that strongly correlate with response of colorectal cancer patients to FOLFOX. Described herein are data structures, data processing, and machine learning models to predict effectiveness of a treatment for a disease or disorder of a subject having a particular set of biomarkers, as well as an exemplary application of such a model to precision medicine, e.g., to methods for selecting a treatment based on a molecular profile, e.g., a treatment comprising administration of 5-fluorouracil/leucovorin combined with oxaliplatin (FOLFOX) or with irinotecan (FOLFIRI).